# Extracorporeal Magnetic Innervation in Combination With Mirabegron in the Treatment of Overactive Bladder

> **NCT06123364** · NA · COMPLETED · sponsor: **Serdinsek Tamara** · enrollment: 56 (actual)

## Conditions studied

- Overactive Bladder
- Overactive Bladder Syndrome

## Interventions

- **DRUG:** mirabegron 50 mg daily
- **DEVICE:** Extracorporeal magnetic innervation (active treatment)
- **DEVICE:** Extracorporeal magnetic innervation (sham treatment)

## Key facts

- **NCT ID:** NCT06123364
- **Lead sponsor:** Serdinsek Tamara
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-14
- **Primary completion:** 2023-04-03
- **Final completion:** 2023-10-01
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2023-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06123364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06123364, "Extracorporeal Magnetic Innervation in Combination With Mirabegron in the Treatment of Overactive Bladder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06123364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*